This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rocchi, P. Articles by Gleave, M. Search for Related Content PubMed PubMed Citation Articles by Rocchi, P. Articles by Gleave, M.

Increased Hsp27 after Androgen Ablation Facilitates Androgen-Independent Progression in Prostate Cancer via Signal Transducers and Activators of Transcription 3–Mediated Suppression of Apoptosis

¹ The Prostate Centre, Vancouver General Hospital; ² Division of Urology, University of British Columbia, Vancouver, British Columbia, Canada; and ³ Department of Urology, University of Washington, Seattle, Washington

Requests for reprints: Martin Gleave, Division of Urology, Vancouver Hospital, University of British Columbia, 27333 Heather Street, Vancouver, British Columbia, Canada V5Z 3J5. Phone: 604-875-5003; Fax: 604-875-5604; E-mail: gleave{at}interchange.ubc.ca.

One strategy to improve therapies in prostate cancer involves targeting cytoprotective genes activated by androgen withdrawal to delay the emergence of the androgen-independent (AI) phenotype. The objectives of this study were to define changes in Hsp27 levels after androgen ablation and to evaluate the functional relevance of these changes in AI progression. Using a tissue microarray of 232 specimens of hormone-naïve and post-hormone ablation–treated prostate cancer, we found that Hsp27 levels increase after androgen ablation to become highly expressed (>4-fold, P 0.01) in AI tumors. Hsp27 overexpression rendered LNCaP cells highly resistant to androgen withdrawal both in vitro and in vivo. Tumor volume and serum prostate–specific antigen levels increased 4.3- and 10-fold faster after castration when Hsp27 was overexpressed. Treatment of LNCaP tumor cells in vitro with Hsp27 antisense oligonucleotides (ASO) or short-interfering RNA suppressed Hsp27 levels in a dose-dependent and sequence-specific manner increased the apoptotic sub–G₀-G₁ fraction and caspase-3 cleavage >2-fold, as well as decreased signal transducers and activators of transcription 3 (Stat3) levels and its downstream genes, c-fos and sPLA-2. The cytoprotection afforded by Hsp27 overexpression was attenuated by Stat3 knockdown using specific Stat3 ASO. Coimmunoprecipitation and immunofluorescence confirmed that Hsp27 interacts with Stat3 and that Stat3 levels correlated directly with Hsp27 levels. Hsp27 ASO treatment in athymic mice bearing LNCaP tumors significantly delayed LNCaP tumor growth after castration, decreasing mean tumor volume and serum prostate–specific antigen levels by 57% and 69%, respectively. These findings identify Hsp27 as a modulator of Stat3-regulated apoptosis after androgen ablation and as a potential therapeutic target in advanced prostate cancer.

This article has been cited by other articles:

				L. Xu, Y. Ding, W. J. Catalona, X. J. Yang, W. F. Anderson, B. Jovanovic, K. Wellman, J. Killmer, X. Huang, K. A. Scheidt, et al. MEK4 Function, Genistein Treatment, and Invasion of Human Prostate Cancer Cells J Natl Cancer Inst, August 19, 2009; 101(16): 1141 - 1155. [Abstract] [Full Text] [PDF]

				N. Kanda and S. Watanabe Leptin Enhances Human {beta}-Defensin-2 Production in Human Keratinocytes Endocrinology, October 1, 2008; 149(10): 5189 - 5198. [Abstract] [Full Text] [PDF]

				J. A. Locke, E. S. Guns, A. A. Lubik, H. H. Adomat, S. C. Hendy, C. A. Wood, S. L. Ettinger, M. E. Gleave, and C. C. Nelson Androgen Levels Increase by Intratumoral De novo Steroidogenesis during Progression of Castration-Resistant Prostate Cancer Cancer Res., August 1, 2008; 68(15): 6407 - 6415. [Abstract] [Full Text] [PDF]

				M. Lakshman, L. Xu, V. Ananthanarayanan, J. Cooper, C. H. Takimoto, I. Helenowski, J. C. Pelling, and R. C. Bergan Dietary Genistein Inhibits Metastasis of Human Prostate Cancer in Mice Cancer Res., March 15, 2008; 68(6): 2024 - 2032. [Abstract] [Full Text] [PDF]

				C. O'Callaghan-Sunol, V. L. Gabai, and M. Y. Sherman Hsp27 Modulates p53 Signaling and Suppresses Cellular Senescence Cancer Res., December 15, 2007; 67(24): 11779 - 11788. [Abstract] [Full Text] [PDF]

				A. Zoubeidi, A. Zardan, E. Beraldi, L. Fazli, R. Sowery, P. Rennie, C. Nelson, and M. Gleave Cooperative Interactions between Androgen Receptor (AR) and Heat-Shock Protein 27 Facilitate AR Transcriptional Activity Cancer Res., November 1, 2007; 67(21): 10455 - 10465. [Abstract] [Full Text] [PDF]

				R. Wu, H. Kausar, P. Johnson, D. E. Montoya-Durango, M. Merchant, and M. J. Rane Hsp27 Regulates Akt Activation and Polymorphonuclear Leukocyte Apoptosis by Scaffolding MK2 to Akt Signal Complex J. Biol. Chem., July 27, 2007; 282(30): 21598 - 21608. [Abstract] [Full Text] [PDF]

				M. Kamada, A. So, M. Muramaki, P. Rocchi, E. Beraldi, and M. Gleave Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells Mol. Cancer Ther., January 1, 2007; 6(1): 299 - 308. [Abstract] [Full Text] [PDF]

				L. Xu and R. C. Bergan Genistein Inhibits Matrix Metalloproteinase Type 2 Activation and Prostate Cancer Cell Invasion by Blocking the Transforming Growth Factor beta-Mediated Activation of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2-27-kDa Heat Shock Protein Pathway Mol. Pharmacol., September 1, 2006; 70(3): 869 - 877. [Abstract] [Full Text] [PDF]